Startups
2026
1-10 Employees
LUCHS Therapeutics (Tx)First-in-Class Tuberculosis Therapy
Tuberculosis kills 3500 people a day and poses a major threat for health care systems worldwide. Multidrug resistant TB is an even bigger challenge as it requires treatment with last-line of defense antibiotics with long and burdensome treatment regimes.
Luchs Tx. sets out to ameliorate this burden. We develop a first-in-class antibiotic, targeting an essential protein in M. tuberculosis that to date has not been addressed using a bespoke, high-throughput assay.
Uniting expertise in biotechnology, medicine and start-up management the founding team transforms biotech developed in years of research into a start-up with a vision of fighting tuberculosis, one of the oldest and most devastating burdens of mankind.
Tuberculosis kills 3500 people a day and poses a major threat for health care systems worldwide. Multidrug resistant TB is an even bigger challenge as it requires treatment with last-line of defense antibiotics with long and burdensome treatment regimes.
Luchs Tx. sets out to ameliorate this burden. We develop a first-in-class antibiotic, targeting an essential protein in M. tuberculosis that to date has not been addressed using a bespoke, high-throughput assay.
Uniting expertise in biotechnology, medicine and start-up management the founding team transforms biotech developed in years of research into a start-up with a vision of fighting tuberculosis, one of the oldest and most devastating burdens of mankind.
Address
Goslar, Germany
Finance Data
| Date | Investors | Amount | Stage |
Financial Overview
No revenue recorded yet